A recent Moya Bio Ltd. patent describes fused azole and furan-based nucleoside analogues acting as ubiquitin-like modifier-activating enzyme 1 (UBA1; UBE1) inhibitors and thus reported to be potentially useful for the treatment of inflammation, cancer, parasitic infections and autoimmune diseases.
Chemocentryx Inc. has described aryl sulfonyl (hydroxy) piperidines acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, endometriosis, periodontitis, rheumatoid arthritis, scleroderma, psoriatic arthritis and inflammatory disorders.
Shanghai Blueray Biopharma Co. Ltd. has divulged polycomb protein EED (PRC2/EED-EZH2 noncatalytic subunit) inhibitors reported to be useful for the treatment of cancer.
Yiteng Pharmaceutical Industry Taizhou Co. Ltd. has synthesized cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Ubix Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising von Hippel-Lindau disease tumor suppressor ligands coupled to a tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety via linker acting as SHP-2 degradation inducers and reported to be useful for the treatment of cancer.
Massachusetts General Hospital and University of California Oakland have described 15-lipoxygenase (LOX) inhibitors reported to be useful for the treatment of stroke, among others.
The Texas Heart Institute Center for Cardiovascular Care has divulged piperazine-based integrin αLβ2 (LFA-1) and/or integrin α4β1 (ITGA4; VLA-4) agonists reported to be useful for the treatment of diabetes, infertility, pulmonary hypertension, renal failure, myocardial infarction, spinal cord injury, pulmonary fibrosis and Parkinson's diseases.
RSS